Research Article| Volume 13, ISSUE 2, P219-226, February 1984

The diuretic effects of CL 115,129 (d,1-15-deoxy-16-hydroxy-16(α/β)-vinyl-prostaglandin E2) and ℓ-prostaglandin E2 in dogs

      This paper is only available as a PDF. To read, Please Download here.


      CL 115,129, the corresponding carboxylic acid and major metabolite of CL 115,347 (d,1-15-deoxy-16-hydroxy-16(α/β)-vinyl-prostaglandin E2 methyl ester), a potent orally and transdermally long acting antihypertensive agent, infused at 0.1 μg/kg/min into the left renal artery of sodium pentobarbital anesthetized beagle dogs increased urinary volume, sodium (Na+), potassium (K+) and chloride (Cl) excretion of the left kidney 289, 201, 101 and 229%, respectively, over the 30 min vehicle-treated control periods. At 0.3 μg/kg/min CL 115,129 caused a 475 and 336% increase in urinary volume and Na , respectively. ℓ-Prostaglandin E2 (ℓ-PGE2) infused at 0.1 μg/kg/min into the left renal artery increased urinary volume, Na+, K+ and Cl excretion of the left kidney of anesthetized beagle dogs 416, 234, 112 and 255%, respectively, over the control. Both CL 115,129 and ℓ-PGE2 did not affect the systemic arterial blood pressure or the electrolyte excretion of the contralateral kidney. It is concluded that in contrast to other conventional vasodilators, which may cause severe water and electrolyte retention, CL 115,347, via its metabolite CL 115,129, may cause diuresis and natriuresis in many clinical settings when used as an antihypertensive.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Prostaglandins, Leukotrienes and Essential Fatty Acids
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Cervoni P.
        • Chan P.S.
        • Lai F.M.
        • Birnbaum J.E.
        CL 115,347 (DHV-PGE2ME). A new orally and topically active prostaglandin antihypertensive agent.
        in: Fed Proc. 42. 1983: 157
        • Chan P.S.
        • Cervoni P.
        • Lai F.
        • Ronsberg M.
        • Stubbs C.S.
        Further studies on CL 115,347 (15-deoxy-16-hydroxy-16-vinyl-prostaglandin E2 methyl ester), a new prostaglandin antihypertensive.
        Pharmacologist. 1982; 24: 138
        • Birnbaum J.E.
        • Chan P.S.
        • Cervoni P.
        • Dessy F.
        • Van Humbeeck K.L.
        Cutaneous erythema and blood pressure lowering effects of topically applied 16vinyl prostaglandins.
        Prostaglandins. 1982; 23: 185
        • Chan P.S.
        • Cervoni P.
        • Ronsberg M.A.
        • Accomando R.C.
        • Quirk G.J.
        • Scully P.A.
        • Lipchuck L.M.
        Antihypertensive activity of (d,l)-15-deoxy-16-hydroxy16(a/s)-vinyl-prostaglandin E2 methyl ester (CL 115,347), A new orally and transdermally long acting antihypertensive agent.
        JPET 236. 1983; (in print)
      1. Ferrara JP. Private communication on unpublished data. Clinical Research, Medical Research Division, American Cyanamid Company, Pearl River, NY, 1982.

        • Dunn M.J.
        • Hood V.L.
        Prostaglandins and the kidney.
        Am J Physiol. 1977; 233: F169
        • Lee J.B.
        • McGiff J.C.
        • Kannegiesser H.
        • Aykent Y.Y.
        • Mudd J.G.
        • Frawley T.F.
        Prostaglandin A1: Antihypertensive and renal effects.
        Ann Int Med. 1971; 74: 703